

Pasi A Ja Nne

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6138433/pasi-a-ja-nne-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

355
papers

73,534
citations

116
h-index

269
g-index

402
ext. papers

84,096
ext. citations

12.2
avg, IF

7.5
L-index

#	Paper	IF	Citations
355	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102752	2.2	14
354	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	3
353	Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.. <i>Nature</i> , 2022 ,	50.4	5
352	Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022 , 128718	2.9	0
351	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.. <i>Nature Cancer</i> , 2022 ,	15.4	7
350	Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.. <i>Nature Communications</i> , 2022 , 13, 2530	17.4	0
349	Phase IB Study of Osimertinib in Combination with Navitoclax in -mutant NSCLC Following Resistance to Initial Therapy (ETCTN 9903). <i>Clinical Cancer Research</i> , 2021 , 27, 1604-1611	12.9	6
348	Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance. <i>Molecular Cancer Therapeutics</i> , 2021 ,	6.1	1
347	A structural model of a Ras-Raf signalosome. <i>Nature Structural and Molecular Biology</i> , 2021 , 28, 847-857	17.6	10
346	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With -Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.. <i>JCO Precision Oncology</i> , 2021 , 5, 1603-1610	3.6	1
345	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021 , 11, 1952-1969	24.4	12
344	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for -Mutant Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
343	Overcoming therapy resistance in EGFR-mutant lung cancer.. <i>Nature Cancer</i> , 2021 , 2, 377-391	15.4	23
342	Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021 , 11, 2488-2505	24.4	11
341	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 811-824	5.4	2
340	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9008-9008	2.2	12
339	Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3097-3097	2.2	1

338	Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.. <i>JCO Precision Oncology</i> , 2021 , 5, 726-732	3.6	2
337	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 551-569	64.1	109
336	Acquired Resistance to KRAS Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 2382-2393	39.2	91
335	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021 , 15, 27-42	7.9	6
334	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. <i>Clinical Cancer Research</i> , 2021 , 27, 34-42	12.9	32
333	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 1019-1028	12.9	14
332	Efficacy of Taletrectinib (AB-106/DS-6051b) in NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100108	1.4	5
331	Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. <i>Clinical Cancer Research</i> , 2021 , 27, 3528-3539	12.9	13
330	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021 , 11, 1688-1699	24.4	57
329	Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	4
328	ERK Inhibitor LY3214996-Based Treatment Strategies for -Driven Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 641-654	6.1	3
327	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2117547	10.4	2
326	Amivantamab: Treating Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3403-3406	2.2	4
325	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer. <i>Science Translational Medicine</i> , 2021 , 13, eabb3738	17.5	0
324	EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd. <i>Cancer Research</i> , 2021 ,	10.1	6
323	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021 ,	24.4	19
322	Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2021 ,	59.2	57
321	Abemaciclib in Combination With Pembrolizumab for Stage IV -Mutant or Squamous NSCLC: A Phase 1b Study. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100234	1.4	4

320	Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
319	Identification of a RAS-activating Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4072-4079	12.9	2
318	Targeting Dysregulation in Cancer. <i>Cancer Discovery</i> , 2020 , 10, 922-934	24.4	26
317	Mutant-Selective Allosteric EGFR Degradere are Effective Against a Broad Range of Drug-Resistant Mutations. <i>Angewandte Chemie - International Edition</i> , 2020 , 59, 14481-14489	16.4	28
316	Mutant-Selective Allosteric EGFR Degradere are Effective Against a Broad Range of Drug-Resistant Mutations. <i>Angewandte Chemie</i> , 2020 , 132, 14589-14597	3.6	9
315	KRAS Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020 , 80, 3719-3731	10.1	17
314	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 4785-4794	12.9	29
313	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020 , 26, 2615-2625	12.9	60
312	Use of Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2393-2403	12.9	12
311	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020 , 37, 104-122.e12	24.3	107
310	A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. <i>Cancer Cell</i> , 2020 , 37, 705-719.e6	24.3	21
309	Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. <i>JCI Insight</i> , 2020 , 5,	9.9	4
308	A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS3651-TPS3651	2.2	15
307	The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. <i>Cancer Discovery</i> , 2020 , 10, 54-71	24.4	413
306	Exploring Targeted Degradation Strategy for Oncogenic KRAS. <i>Cell Chemical Biology</i> , 2020 , 27, 19-31.e6	8.2	102
305	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. <i>Lung Cancer</i> , 2020 , 140, 35-41	5.9	12
304	Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation?. <i>Transplantation</i> , 2020 , 104, e79-e80	1.8	1
303	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC 2020 , 8,		24

302	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. <i>Cancer Discovery</i> , 2020 , 10, 688-701	24.4	104
301	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019 , 133, 96-102	5.9	53
300	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. <i>Cancer Discovery</i> , 2019 , 9, 926-943	24.4	110
299	Everolimus in Anaplastic Thyroid Cancer: A Case Series. <i>Frontiers in Oncology</i> , 2019 , 9, 106	5.3	17
298	An unbiased screen for activating epidermal growth factor receptor mutations. <i>Journal of Biological Chemistry</i> , 2019 , 294, 9377-9389	5.4	6
297	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1448-1455	13.4	42
296	A dominant-negative effect drives selection of missense mutations in myeloid malignancies. <i>Science</i> , 2019 , 365, 599-604	33.3	127
295	The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. <i>Cancer Immunology Research</i> , 2019 , 7, 1457-1471	12.5	53
294	Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2019 , 95, 120-126	4.4	18
293	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. <i>Cancer Research</i> , 2019 , 79, 4439-4452	10.1	23
292	Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 1549-1553	4.3	25
291	An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. <i>EBioMedicine</i> , 2019 , 49, 106-117	8.8	9
290	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1995-2002	8.9	34
289	Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9007-9007	2.2	43
288	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019 , 125, 892-901	6.4	78
287	Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 4249-4255	8.3	95
286	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. <i>Melanoma Research</i> , 2018 , 28, 89-95	3.3	11
285	Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver. <i>Clinical Cancer Research</i> , 2018 , 24, 1775-1776	12.9	4

284	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018 , 172, 857-868.e15	56.2	142
283	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. <i>Clinical Cancer Research</i> , 2018 , 24, 1546-1553	12.9	52
282	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018 , 24, 4437-4443	14.3	210
281	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018 , 4, 1527-1534	13.4	342
280	Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5963-5976	12.9	42
279	Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. <i>Angewandte Chemie</i> , 2018 , 130, 11803-11807	3.6	2
278	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. <i>Clinical Lung Cancer</i> , 2018 , 19, e655-e665	4.9	4
277	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018 , 50, 1271-1281	36.3	249
276	TGF β pathway inhibition in the treatment of non-small cell lung cancer. <i>Pharmacology & Therapeutics</i> , 2018 , 184, 112-130	13.9	46
275	Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 841-849	2.2	291
274	Outcomes by , , and Genotype After Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-18	3.6	2
273	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018 , 6, 1511-1523	12.5	39
272	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. <i>Lung Cancer</i> , 2018 , 126, 72-79	5.9	38
271	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648
270	Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2018 , 57, 11629-11633	16.4	15
269	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 204-213	12.9	57
268	EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 884-889	8.9	19
267	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , 2017 , 19, 787-795	8.1	34

266	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1288-1296	2.2	363
265	EGFR T790M mutation testing within the osimertinib AURA Phase I study. <i>Lung Cancer</i> , 2017 , 109, 9-13	5.9	19
264	Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1061-1070	8.9	178
263	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1844-1853	27.4	211
262	Discovery of a potent dual ALK and EGFR T790M inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2017 , 136, 497-510	6.8	19
261	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1247-1256	8.9	40
260	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017 , 77, 2712-2721	10.1	81
259	MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S440-S441	8.9	24
258	P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S952-S953	8.9	2
257	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1072-S1073	8.9	3
256	P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1080-S1081	8.9	4
255	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S251-S252	8.9	12
254	A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 923-932	3.5	29
253	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , 2017 , 14, 37-50	2.2	13
252	KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. <i>ELife</i> , 2017 , 6,	8.9	56
251	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1403-1410	2.2	198
250	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1588-1594	8.9	16
249	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. <i>Clinical Cancer Research</i> , 2017 , 23, 6661-6672	12.9	77

248	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. <i>Cell Chemical Biology</i> , 2017 , 24, 1008-1016	12.9	55
247	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017 , 23, 5737-5744	12.9	55
246	Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2367-2373	12.9	22
245	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017 , 2, e000219	6	62
244	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 92265-92274	3.3	10
243	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2781-2789	2.2	1
242	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016 , 22, 1103-10	12.9	282
241	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 915-22	12.9	177
240	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1387-96	8.9	6
239	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. <i>Cancer</i> , 2016 , 122, 3456-3463	6.4	11
238	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical Cancer Research</i> , 2016 , 22, 5130-5140	12.9	397
237	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016 , 4, 1038-1048	12.5	54
236	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 6010-6020	12.9	84
235	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 850-61	8.9	57
234	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3375-82	2.2	605
233	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 613-638	8.9	164
232	Oncologists and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. <i>Genetics in Medicine</i> , 2016 , 18, 1011-9	8.1	84
231	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3148-56	12.9	49

230	Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1). <i>Clinical Lung Cancer</i> , 2016 , 17, e1-4	4.9	25
229	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 767-76	3.5	88
228	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 737-747	8.9	42
227	Progress on Covalent Inhibition of KRAS(G12C). <i>Cancer Discovery</i> , 2016 , 6, 233-4	24.4	14
226	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2016 , 4, 289-93	12.5	112
225	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 556-65	8.9	176
224	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. <i>Journal of Clinical Oncology</i> , 2016 , 34, 721-30	2.2	383
223	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 313-20	13.4	106
222	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. <i>JCI Insight</i> , 2016 , 1, e89014	9.9	79
221	Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. <i>JAMA Oncology</i> , 2016 , 2, 1240-2	13.4	12
220	Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 3501-12	3.4	20
219	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. <i>Nature</i> , 2016 , 534, 129-32	50.4	414
218	Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. <i>JAMA Oncology</i> , 2016 , 2, 1014-22	13.4	412
217	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016 , 98, 1051-1066	11	107
216	Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1334-1341	24.4	94
215	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016 , 8, 79	14.4	109
214	Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. <i>Cell</i> , 2015 , 160, 977-989	56.2	237
213	Development of small molecules targeting the pseudokinase Her3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015 , 25, 3382-9	2.9	38

212	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1689-99	59.2	1447
211	Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. <i>Cancer</i> , 2015 , 121, 2570-7	6.4	35
210	Enhanced ratio of signals enables digital mutation scanning for rare allele detection. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 284-92	5.1	23
209	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015 , 21, 560-2	50.5	1021
208	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2851-60	12.9	72
207	A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). <i>Journal of Thoracic Oncology</i> , 2015 , 10, 143-7	8.9	34
206	A functional landscape of resistance to ALK inhibition in lung cancer. <i>Cancer Cell</i> , 2015 , 27, 397-408	24.3	123
205	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015 , 33, 1108-14	4.3	39
204	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015 , 3, 1333-1343	12.5	25
203	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015 , 75, 4372-83	10.1	83
202	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1726-35	8.9	155
201	Clinical Implications of Variant ALK FISH Rearrangement Patterns. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1648-52	8.9	44
200	Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 951-9	8.9	68
199	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015 , 6, 6377	17.4	358
198	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015 , 75, 3139-46	10.1	26
197	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2015 , 21, 3913-23	12.9	256
196	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2015 , 5, 960-971	24.4	142
195	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015 , 3, 855-63	12.5	53

194	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 5439-44	12.9	76
193	Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 9296-9308	8.3	30
192	Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. <i>Molecular Oncology</i> , 2015 , 9, 260-9	7.9	43
191	Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. <i>Oncotarget</i> , 2015 , 6, 11357-68	3.3	13
190	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2014 , 120, 2289-98	6.4	25
189	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. <i>Nature Medicine</i> , 2014 , 20, 682-8	50.5	406
188	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. <i>Clinical Cancer Research</i> , 2014 , 20, 1698-1705	12.9	580
187	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. <i>Clinical Cancer Research</i> , 2014 , 20, 1204-1211	12.9	49
186	Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. <i>Angewandte Chemie - International Edition</i> , 2014 , 53, 199-204	16.4	223
185	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1433-1441	21.7	92
184	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1369-78	21.7	109
183	Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. <i>Lung Cancer</i> , 2014 , 86, 241-6	5.9	60
182	Pharmacological targeting of the pseudokinase Her3. <i>Nature Chemical Biology</i> , 2014 , 10, 1006-12	11.7	123
181	Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers. <i>Clinical Cancer Research</i> , 2014 , 20, 4193-9	12.9	20
180	Response and acquired resistance to everolimus in anaplastic thyroid cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1426-33	59.2	237
179	Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. <i>Molecular Cancer Research</i> , 2014 , 12, 1055-66	6.6	32
178	Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. <i>Cancer Cell</i> , 2014 , 25, 590-604	24.3	273
177	A severe photosensitivity dermatitis caused by crizotinib. <i>Journal of Thoracic Oncology</i> , 2014 , 9, e51-e53	8.9	14

176	Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. <i>PLoS ONE</i> , 2014 , 9, e95303	3.7	47
175	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 6551-8	12.9	67
174	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E4869-77	11.5	125
173	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. <i>Cancer</i> , 2014 , 120, 1145-54	6.4	100
172	Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. <i>Cell Reports</i> , 2014 , 7, 1824-32	10.6	19
171	Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 316-23	8.9	31
170	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. <i>European Respiratory Review</i> , 2014 , 23, 356-66	9.8	105
169	Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 126-31	8.9	22
168	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8009-8009	2.2	63
167	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. <i>Cancer</i> , 2013 , 119, 3761-8	6.4	37
166	The quest to overcome resistance to EGFR-targeted therapies in cancer. <i>Nature Medicine</i> , 2013 , 19, 1389-400	5.0	684
165	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. <i>Nature Medicine</i> , 2013 , 19, 1469-1472	2.5	420
164	Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. <i>Cancer Research</i> , 2013 , 73, 2574-86	10.1	135
163	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. <i>Cancer Research</i> , 2013 , 73, 6770-9	10.1	61
162	Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. <i>Cancer Discovery</i> , 2013 , 3, 1355-63	24.4	831
161	New targetable oncogenes in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1097-104	2.2	249
160	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , 2013 , 14, 38-47	21.7	536
159	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. <i>Cancer Research</i> , 2013 , 73, 834-43	10.1	153

158	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 2385-94	59.2	2594
157	RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. <i>American Journal of Roentgenology</i> , 2013 , 201, W64-71	5.4	31
156	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 4532-40	12.9	238
155	Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. <i>Cancer Discovery</i> , 2013 , 3, 870-9	24.4	93
154	Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. <i>Clinical Cancer Research</i> , 2013 , 19, 1634-6	12.9	7
153	Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 3078-87	12.9	68
152	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2173-81	2.2	214
151	Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 179-84	8.9	182
150	Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1059-68	8.9	38
149	Epidermal growth factor receptor inhibition in lung cancer: status 2012. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 373-84	8.9	99
148	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8029-8029	2.2	14
147	The introduction of systematic genomic testing for patients with non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1767-1774	8.9	80
146	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , 2012 , 13, 1011-9	21.7	983
145	Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. <i>Clinical Cancer Research</i> , 2012 , 18, 3737-42	12.9	64
144	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. <i>Cancer Discovery</i> , 2012 , 2, 934-44	47.4	212
143	Zeroing in on ROS1 rearrangements in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4222-29	2.9	26
142	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell</i> , 2012 , 150, 1107-20	50	1304
141	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 1790-7	12.9	115

140	An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFR and kit. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 4579-84	2.9	11
139	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. <i>Cancer Treatment Reviews</i> , 2012 , 38, 416-30	14.4	97
138	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. <i>Nature</i> , 2012 , 483, 613-7	50.4	361
137	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. <i>Nature Medicine</i> , 2012 , 18, 382-4	50.5	664
136	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2063-9	2.2	197
135	Circumventing cancer drug resistance in the era of personalized medicine. <i>Cancer Discovery</i> , 2012 , 2, 214-26	24.4	348
134	Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. <i>Bioscience Reports</i> , 2012 , 32, 413-22	4.1	25
133	Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. <i>Clinical Cancer Research</i> , 2012 , 18, 380-91	12.9	59
132	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. <i>Cancer Research</i> , 2012 , 72, 3302-11	10.1	90
131	c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. <i>Melanoma Research</i> , 2012 , 22, 123-32	3.3	37
130	Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2509-15	2.2	154
129	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 963-72	8.9	25
128	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. <i>Cancer Discovery</i> , 2011 , 1, 608-25	24.4	108
127	CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. <i>Academic Radiology</i> , 2011 , 18, 54-62	4.3	69
126	Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011 , 2, 379-384	4.3	27
125	Imaging of lung cancer in the era of molecular medicine. <i>Academic Radiology</i> , 2011 , 18, 424-36	4.3	33
124	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 78-89	24.4	389
123	KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 220-2	8.9	

122	Discovery of selective irreversible inhibitors for EGFR-T790M. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 638-43	2.9	54
121	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. <i>Cancer Research</i> , 2011 , 71, 1081-91	10.1	164
120	New strategies for treatment of ALK-rearranged non-small cell lung cancers. <i>Clinical Cancer Research</i> , 2011 , 17, 7213-8	12.9	72
119	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. <i>Cancer Research</i> , 2011 , 71, 6051-60	10.1	468
118	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 1131-9	12.9	148
117	Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2140-8	12.9	109
116	Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. <i>Science Translational Medicine</i> , 2011 , 3, 99ra86	17.5	463
115	Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. <i>Cancer Research</i> , 2011 , 71, 5965-75	10.1	12
114	Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR. <i>Clinical Chemistry</i> , 2011 , 57, 770-3	5.5	12
113	Resistance to Targeted Therapies As a Result of Mutation(s) in the Target 2011 , 1-31		
112	A new device for rapid isolation by size and characterization of rare circulating tumor cells. <i>Anticancer Research</i> , 2011 , 31, 427-41	2.3	256
111	Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. <i>Cancer Science</i> , 2010 , 101, 167-72	6.9	56
110	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010 , 463, 899-905	50.4	2590
109	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. <i>New England Journal of Medicine</i> , 2010 , 363, 1727-33	59.2	622
108	A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. <i>Clinical Cancer Research</i> , 2010 , 16, 1561-71	12.9	364
107	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. <i>Cancer Research</i> , 2010 , 70, 10038-43	10.1	264
106	TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 2785-92	6.1	64
105	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 357-60	2.2	615

104	EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2010 , 133, 922-34	1.9	92
103	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
102	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. <i>Cancer Research</i> , 2010 , 70, 9827-36	10.1	164
101	New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. <i>American Journal of Roentgenology</i> , 2010 , 195, W221-8	5.4	153
100	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4953-60	2.2	296
99	A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1655-61	8.9	100
98	Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1382-90	8.9	110
97	Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. <i>Human Genetics</i> , 2010 , 127, 573-82	6.3	61
96	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2010 , 17, 77-88	24.3	816
95	Malignant Mesothelioma 2010 , 160-168		
94	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. <i>Clinical Cancer Research</i> , 2009 , 15, 5267-73	12.9	328
93	Integration of molecular profiling into the lung cancer clinic. <i>Clinical Cancer Research</i> , 2009 , 15, 5317-22	12.9	73
92	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 2630-6	12.9	206
91	Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. <i>Clinical Cancer Research</i> , 2009 , 15, 907-13	12.9	44
90	A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 2552-8	12.9	230
89	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 7502-7509	12.9	115
88	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2009 , 15, 3484-94	12.9	244
87	Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. <i>Clinical Chemistry</i> , 2009 , 55, 748-56	5.5	51

86	EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. <i>Cancer Cytopathology</i> , 2009 , 117, 67-72	3.9	100
85	Treatment of peritoneal mesothelioma in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 127-9	3	11
84	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009 , 462, 1070-4	50.4	766
83	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2009 , 8, 709-23	64.1	259
82	Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. <i>Cancer Letters</i> , 2009 , 282, 14-24	9.9	49
81	Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. <i>Cancer Research</i> , 2009 , 69, 8341-8	10.1	100
80	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. <i>Clinical Cancer Research</i> , 2009 , 15, 5216-23	12.9	560
79	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 809-15	8.9	127
78	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. <i>Lung Cancer</i> , 2008 , 60 Suppl 2, S3-9	5.9	61
77	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2442-9	2.2	725
76	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2895-9	12.9	576
75	EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 4275-83	12.9	774
74	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. <i>Clinical Cancer Research</i> , 2008 , 14, 6963-73	12.9	106
73	Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1465-71	2.2	46
72	Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 5941-6	12.9	92
71	Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. <i>Clinical Cancer Research</i> , 2008 , 14, 3860-6	12.9	47
70	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. <i>Clinical Cancer Research</i> , 2008 , 14, 7060-7	12.9	135
69	Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3567-72	2.2	96

68	Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. <i>Cancer</i> , 2008 , 113, 808-14	6.4	98
67	Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. <i>Lung Cancer</i> , 2007 , 55, 187-94	5.9	24
66	LKB1 modulates lung cancer differentiation and metastasis. <i>Nature</i> , 2007 , 448, 807-10	50.4	774
65	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. <i>Cancer Cell</i> , 2007 , 12, 81-93	24.3	193
64	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. <i>Science</i> , 2007 , 316, 1039-43	33.3	3705
63	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3936-44	2.2	105
62	s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. <i>Nucleic Acids Research</i> , 2007 , 35, e84	20.1	20
61	Does erlotinib improve symptoms in patients with lung cancer?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 146-7		2
60	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. <i>Cancer Research</i> , 2007 , 67, 11924-32	10.1	589
59	Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. <i>Cancer Research</i> , 2007 , 67, 4933-9	10.1	134
58	Ras pathway activation in malignant mesothelioma. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 789-95	8.9	26
57	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2248-55	2.2	198
56	Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. <i>Oncologist</i> , 2007 , 12, 90-8	5.7	138
55	Phase II clinical trial of chemotherapy-naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 760-6	2.2	279
54	Fulminant hepatic failure secondary to erlotinib. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 917-20	20.9	35
53	Impact of EGFR mutations on treatment of non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 5-9	3.5	3
52	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. <i>Cancer Cell</i> , 2006 , 9, 485-95	24.3	389
51	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. <i>Clinical Cancer Research</i> , 2006 , 12, 6049-55	12.9	173

50	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4436s-4440s	12.9	29
49	A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. <i>Clinical Cancer Research</i> , 2006 , 12, 751-8	12.9	199
48	Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5253-8	2.2	163
47	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Clinical Cancer Research</i> , 2006 , 12, 4416s-4420s	12.9	113
46	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. <i>Clinical Cancer Research</i> , 2006 , 12, 4403s-4408s	12.9	68
45	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2006 , 12, 3908-14	12.9	479
44	Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4517-20	2.2	210
43	A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. <i>Blood</i> , 2006 , 107, 1237-8	2.2	17
42	Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 506-512	8.9	42
41	Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 506-512	8.9	46
40	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. <i>Nature Medicine</i> , 2006 , 12, 852-5	50.5	283
39	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. <i>Journal of Clinical Investigation</i> , 2006 , 116, 2695-706	15.9	372
38	Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 506-12	8.9	17
37	Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. <i>Oncology</i> , 2005 , 68, 500-10	3.6	17
36	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5900-9	2.2	1250
35	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. <i>New England Journal of Medicine</i> , 2005 , 352, 786-92	59.2	3250
34	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. <i>Seminars in Oncology</i> , 2005 , 32, S9-15	5.5	69
33	Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. <i>Clinical Lung Cancer</i> , 2005 , 7, 40-6	4.9	147

32	Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. <i>Cancer Research</i> , 2005 , 65, 7525-9	10.1	130
31	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. <i>PLoS Medicine</i> , 2005 , 2, e313	11.6	527
30	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3227-34	2.2	343
29	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. <i>Cancer Research</i> , 2005 , 65, 5561-70	10.1	285
28	Factors predicting response to EGFR tyrosine kinase inhibitors. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005 , 26, 314-22	3.9	18
27	Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005 , 26, 342-52	3.9	18
26	Responsiveness to cetuximab without mutations in EGFR. <i>New England Journal of Medicine</i> , 2005 , 353, 208-9	59.2	111
25	Inhibition of the met receptor in mesothelioma. <i>Clinical Cancer Research</i> , 2005 , 11, 8122-30	12.9	62
24	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3788-93	11.5	437
23	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1185-94	9.7	268
22	Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 235-7	2.2	10
21	Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. <i>Cancer Research</i> , 2005 , 65, 8968-74	10.1	145
20	An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. <i>Cancer Research</i> , 2004 , 64, 3060-71	10.1	447
19	Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. <i>Cancer Research</i> , 2004 , 64, 7241-4	10.1	316
18	High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. <i>Oncogene</i> , 2004 , 23, 2716-26	9.2	91
17	Patterns of failure following surgical resection for malignant pleural mesothelioma. <i>Thoracic Surgery Clinics</i> , 2004 , 14, 567-73	3.1	46
16	Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. <i>Lung Cancer</i> , 2004 , 44, 221-30	5.9	185
15	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. <i>Science</i> , 2004 , 304, 1497-500	33.3	7937

14	Chemotherapy for malignant pleural mesothelioma. <i>Clinical Lung Cancer</i> , 2003 , 5, 98-106	4.9	42
13	The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma. <i>Annals of Medicine</i> , 2003 , 35, 450-7	1.5	3
12	Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. <i>Clinical Cancer Research</i> , 2003 , 9, 1698-704	12.9	8
11	Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5915-21	12.9	2
10	Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2002 , 3 Suppl 2, S37-41	4.9	2
9	Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. <i>Cancer</i> , 2002 , 95, 1528-38	6.4	119
8	Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. <i>Cancer Research</i> , 2002 , 62, 5242-7	10.1	92
7	Disrupted sperm function and fertilin beta processing in mice deficient in the inositol polyphosphate 5-phosphatase Inpp5b. <i>Developmental Biology</i> , 2001 , 240, 641-53	3.1	38
6	Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2927-9	2.2	8
5	Chemoprevention of colorectal cancer. <i>New England Journal of Medicine</i> , 2000 , 342, 1960-8	59.2	379
4	Lung cancer presenting with solitary bone metastases. Case 2: acrometastasis as an initial presentation of non-small-cell lung carcinoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2998-3001	2.2	13
3	Screening for homologous recombination in ES cells using RT-PCR. <i>BioTechniques</i> , 1997 , 22, 22-4, 26	2.5	
2	Physical mapping and genomic structure of the Lowe syndrome gene OCRL1. <i>Human Genetics</i> , 1997 , 99, 145-50	6.3	78
1	Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens. <i>Genomics</i> , 1995 , 28, 280-5	4.3	9